Julia Kanapathippillai

The High Court will hear the appeal of a failed class action over the planned demolition of inner-city public housing towers in Melbourne, which will involve consideration of the right to remain in settled social communities.

The former CEO of the Australian Film Institute, who alleges he was ousted through a sham redundancy, has dropped his bid for reinstatement.

Fletcher Building has sold a South Australian industrial property to an unnamed investor for $20.05 million.

Former CFMEU Victorian secretary John Setka has reached an agreement with the Fair Work Ombudsman in proceedings alleging he tried to coerce the AFL to sack an umpire over his previous role at the Australian Building and Construction Commission.

Queensland developer Azure has partially won a security of payment spat, with a judge finding an adjudicator erred in finding it owes $1.7 million to a contractor for works on a luxury apartment building.

LG Australia has defeated an appeal of a decision which found it did not breach the duty of care owed to the owners of a refrigerator which caught fire, who were not provided with a replacement through a recall process.

The High Court of Australia will hear the appeal of a failed class action over the planned demolition of inner-city public housing towers in Melbourne, which will involve consideration of the right to remain in settled social communities.

A judge has permanently stayed a suit against developer Stennson over a Caulfield North residential development after finding the developer would suffer prejudice because the builder on the project was not a party in the case.

A landlord has won its bid to have lost rent and outgoings assessed as part of damages it is owed after a judge found baked goods producer Allied Pinnacle was required to repaint the outside when its commercial lease at a Western Sydney property ended.

Trial in AstraZeneca's patent infringement case over Pharmacor's plans to launch a cheaper version of diabetes drug Forxiga has been delayed to October, after the generic drug maker got the all-clear to revise its cross-claim.